A Study to Evaluate ALN-4915 in Adult Healthy Volunteers

A Phase 1, Randomized, Double-Masked, Placebo-controlled, Single Ascending Dose Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALN-4915 in Adult Healthy Volunteers

The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of ALN-4915.

Inclusion Criteria:

• Is willing and able to complete all study assessments

Exclusion Criteria:

• Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >upper limit of normal (ULN)
• Has total bilirubin >ULN
• Has no history of invasive infection by an encapsulated organism
• Has no known complement or immunologic deficiency